Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as January.

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Diabetic medicine Ozempic now approved by Health Canada to reduce the risk of further kidney decline among patients with Type ...

Health Canada has approved Ozempic in an effort to help reduce the risk of kidney decline for patients living with Type 2 ...

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

GLP-1 receptor agonist medications like Ozempic have been talked about so much that its side effects (like nausea and ...

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the ...

TORONTO — Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes ...

The weight loss injectable Ozempic has faced several lawsuits in 2025 from people who had a negative experience with the ...

Novo Nordisk’s preliminary update for the first six months of 2025 reported an 18% sales increase and 29% operating profit growth at CER, driven primarily by its GLP-1 drugs, Ozempic and Wegovy.

If the shoe fits. Ozempic and other weight loss drugs could have a gnarly side effect dubbed “Ozempic-feet,” according to a report. The popular pound-shedding prescription drug is known… ...

GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk and decreased cancer risk to addiction treatment.